This review explains the science behind cold tumor hot tumor immunotherapy how to switch, focusing on how nanocarrier delivery may reshape treatment precision in ongoing research.
The Problem Isn’t the Immune System. It’s the Address.
Most people researching cold tumor hot tumor immunotherapy how to switch eventually land on the same frustrating wall: therapies that work brilliantly in some patients do almost nothing in others. The assumption that follows is usually that the immune system simply isn’t strong enough, or that the tumor is too clever. That assumption is worth examining, because a growing body of research points somewhere else entirely, toward the problem of delivery.
What’s Actually at Stake
For patients with tumors that have been described as “cold,” meaning the immune system isn’t recognizing or entering them, the question isn’t only which drug but how to get it there without damaging the surrounding tissue in the process. A review published in the Journal of Translational Medicine synthesizes the current science on nanocarrier-based immunotherapy. By the end of this post you’ll understand why the delivery mechanism may matter as much as the drug itself.
The Gap the Field Has Been Working Around
Checkpoint inhibitors, CAR-T cells, cancer vaccines: each of these was developed to attack tumors through a single mechanism. Oncologists weren’t wrong to pursue them individually. Each approach reflected the best available science at the time, and each has produced real results in specific cancers. The problem is that a single mechanism, delivered systemically, often can’t get immune cells into a cold tumor, keep them there, and simultaneously override the tumor’s immune-suppressing environment. When researchers have tried to boost the immune response more aggressively by adding cytokines, for example, the whole-body toxicity becomes its own crisis.
A Better Way to Think About Delivery
Think of conventional cancer drugs as bulk mail dropped across an entire neighborhood: most of it lands at the wrong address, disrupting households that never asked for it. Nanocarriers work more like GPS-tracked packages addressed to a single specific recipient, fitted with a lock that only opens when the package detects the right chemical doorstep.
In this analogy, the neighborhood is the body, the wrong addresses are healthy tissues that suffer side effects, and the chemical doorstep is the tumor’s distinctive acidity or enzyme signature that triggers cargo release. The nanocarrier itself, a particle engineered to be between 1 and 100 nanometers across, thousands of times smaller than a grain of sand, is the locked package. The cargo inside can be a drug, a strand of RNA, a protein, or even a gene-editing tool. In preclinical models, this precision means therapeutic compounds concentrate at the tumor site rather than circulating freely through the body, which is exactly what the review describes happening across multiple nanocarrier types.
What the Science Shows
Nanocarriers can be designed to release their contents in response to signals that are specific to tumor tissue, including its characteristic acidity and the enzymes it produces. That responsive release is what makes it possible to carry multiple immune-activating payloads at once without triggering systemic toxicity. Instead of one mechanism working in isolation, several anti-cancer pathways can be activated simultaneously inside the tumor. The delivery can be targeted not just to the tumor as a whole but to specific compartments inside individual tumor cells.
The scale of development here reflects where pharmaceutical investment is heading. As of 2022, about half of nanopharmaceuticals developed as cancer treatments are lipid-based nanocarriers, making them the dominant class of cancer nanomedicine in development. This is a review paper synthesizing existing preclinical and clinical research across multiple nanocarrier types and immunotherapy strategies. It does not present original patient data, and it would be inaccurate to read any single finding within it as established clinical efficacy. What it does provide is a coherent map of where the evidence is pointing.
TAM’s Role in This Work
This review was co-authored by Francesco Marincola, who is affiliated with TAM Center. His inclusion in a paper synthesizing the intersection of nanocarrier engineering and cancer immunotherapy reflects TAM’s ongoing work at the boundary between translational science and immune-based treatment strategies.
What Comes Next
The more precise question the field is now asking is not whether nanocarriers can deliver multiple payloads, but which combinations of payloads, in which sequences, produce durable immune responses in which tumor types. Turning a cold tumor hot has never been purely a question of finding the right drug. It has also been a question of getting the right combination to the right place without creating a systemic crisis in the process. This research direction doesn’t resolve that question, but it sharpens it considerably. That’s what useful science does.
Stay Informed
If you or someone you care for is navigating a cancer diagnosis where immunotherapy hasn’t worked or hasn’t been offered, understanding the delivery problem is a reasonable place to focus. Ask your oncologist specifically about the tumor microenvironment and whether nanocarrier-based approaches are being studied for your cancer type. The research is preclinical and ongoing, but the questions it raises are ones you can bring into the room.
Source
Hu J; Arvejeh PM; Bone S; Hett E; Marincola FM; Roh KH. “Nanocarriers for cutting-edge cancer immunotherapies.” Journal of Translational Medicine 2025;23(1):447. doi:10.1186/s12967-025-06435-0. https://doi.org/10.1186/s12967-025-06435-0
Source
Hu J; Arvejeh PM; Bone S; Hett E; Marincola FM; Roh KH. “Nanocarriers for cutting-edge cancer immunotherapies.” Journal of Translational Medicine 2025;23(1):447. doi:10.1186/s12967-025-06435-0. https://doi.org/10.1186/s12967-025-06435-0
Frequently Asked Questions
Nanocarriers are engineered to exploit features that are specific to tumor tissue, such as higher acidity or the presence of certain enzymes. When the particles reach that environment, those conditions act as a trigger that causes the carrier to release its payload. This means the drugs deposit where the tumor is, rather than circulating freely through the whole body.
A cold tumor is one the immune system is largely ignoring, either because it lacks the signals that attract immune cells or because the tumor has created a suppressive environment around itself. Many immunotherapy drugs fail against cold tumors precisely because the immune response never gets started. Nanocarriers are being studied as a way to deliver immune-activating agents directly into that suppressive environment to try to convert cold tumors into ones the immune system will recognize and attack.
This is a review paper, meaning the authors synthesized findings from existing preclinical and clinical research rather than running their own patient trial. The review concludes that nanocarriers show promise for improving immunotherapy by delivering multiple cancer-fighting agents to tumors simultaneously and activating more than one immune attack pathway at once. No original patient data was generated, and the findings reflect the current direction of the field rather than established clinical results.
Many immune-boosting cancer drugs cause serious side effects when they circulate throughout the body, because they can trigger immune activity in healthy tissue as well as in tumors. Targeted delivery concentrates the drug at the tumor site, which reduces the amount of drug affecting other organs. The goal is to keep the therapeutic effect high at the tumor while lowering the systemic exposure that drives toxicity.
Lipid-based nanocarriers are particles built from fatty molecules, similar in structure to the membranes that surround human cells. As of 2022, roughly half of all nanopharmaceuticals in development for cancer are lipid-based, making them the most common class in this research space. Their prevalence is partly due to their compatibility with biological tissue and their established track record in other approved medicines, such as certain mRNA vaccines.
Yes, Francesco Marincola of TAM Center is listed as a co-author on this review paper. His involvement reflects TAM Center’s ongoing interest in cancer immunotherapy research and in synthesizing emerging science around immune-based treatment strategies.
No. This paper is a review of existing research, not a clinical trial, and it does not represent an available treatment. Nanocarrier-based immunotherapy approaches are at various stages of preclinical and clinical investigation depending on the specific combination and cancer type. Anyone interested in experimental cancer immunotherapy options should speak with their oncologist about currently enrolling clinical trials.
Interested in what targeted diagnostics could reveal about your own biology? Start with a conversation with the TAM Center team.
Schedule a Consultation